Biomerica, Inc. Hits New 52-Week Low at $1.79 Amid Declining Sales

Biomerica, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.79 as of June 18, 2026. This significant decline marks a stark contrast to its 52-week high of USD 4.60, reflecting a challenging year for the company with a performance drop of 60.75%. The company's market capitalization stands at approximately USD 6 million, indicating its small size within the industry. Biomerica has reported a negative return on equity of -90.76%, highlighting ongoing financial difficulties. Additionally, the company has experienced a decline in net sales, which have contracted at an annual rate of -7.03% over the past five years. The recent financial results further underscore the company's struggles, with net sales for the half-year period reported at USD 2.2 million, down 20.25%, and a pre-tax profit loss of USD 1.3 million, reflecting a 29.88% decrease. Institutional investor participation has also waned, with a 1.27% reduction in stakes over the previous quarter, now holding 11.95% of the company. These factors contribute to a challenging environment for Biomerica as it navigates its current market position.